Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H16O5 |
| Molecular Weight | 324.3273 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CC(C1=CC=CC=C1)C2=C(O)C3=C(OC2=O)C=C(O)C=C3
InChI
InChIKey=SKFYEJMLNMTTJA-UHFFFAOYSA-N
InChI=1S/C19H16O5/c1-11(20)9-15(12-5-3-2-4-6-12)17-18(22)14-8-7-13(21)10-16(14)24-19(17)23/h2-8,10,15,21-22H,9H2,1H3
| Molecular Formula | C19H16O5 |
| Molecular Weight | 324.3273 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:47:08 GMT 2023
by
admin
on
Sat Dec 16 08:47:08 GMT 2023
|
| Record UNII |
B92SFW09LJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10939074
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
17834-03-6
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
B92SFW09LJ
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY | |||
|
54682507
Created by
admin on Sat Dec 16 08:47:09 GMT 2023 , Edited by admin on Sat Dec 16 08:47:09 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE INACTIVE |
Formation rate is higher for S isomer; metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that modulates the in vivo anticoagulant activity of warfarin.
URINE
|
